HCW Biologics (HCWB) Q2 2024 earnings summary

Executive summary

• Net loss for Q2 2024 was $15.3M, up from $4.3M in Q2 2023, driven by a sharp increase in legal expenses related to arbitration and settlement activities.

• Revenues for Q2 2024 were $619K, nearly flat year-over-year, derived solely from supply agreements with Wugen.

• The company completed a major legal settlement in July 2024, resolving arbitration and litigation with ImmunityBio, Altor/NantCell, and affiliates, eliminating future legal uncertainty but incurring significant legal costs.

• Launched new financing plans, including equity offerings, secured notes, and out-licensing discussions, with $8M raised in 2024.

• Substantial doubt remains about the company's ability to continue as a going concern due to low cash reserves and ongoing losses.

Financial highlights

• Q2 2024 net loss: $15.3M vs. $4.3M in Q2 2023; six-month net loss: $22.7M vs. $9.4M prior year.

• Legal expenses surged to $10.4M in Q2 2024 from $1.4M in Q2 2023, mainly due to arbitration.

• Revenue for six months ended June 30, 2024: $1.75M, up from $665K in the prior year period.

• Cash and cash equivalents at June 30, 2024: $1.2M, down from $3.6M at year-end 2023.

• Gross margin improved in H1 2024 due to lower cost of revenues, but overall operating expenses far exceed revenues.

Outlook and guidance

• Management expects continued operating losses and recognizes the need to raise additional capital to fund operations and clinical development.

• Financing plans include up to $10M in secured notes (with $5.5M issued as of August 2024), equity raises, and potential business development transactions.

• If unable to secure additional funding, the company may need to curtail or cease operations.

• Received Nasdaq deficiency notices for market value and minimum bid price; has 180 days to regain compliance.

• Ongoing efforts to maintain Nasdaq listing, but no assurance of compliance.